TY - JOUR
T1 - 18 F-FEDAC as a targeting agent for activated macrophages in DBA/1 mice with collagen-induced arthritis
T2 - Comparison with 18 F-FDG
AU - Chung, Seock Jin
AU - Yoon, Hai Jeon
AU - Youn, Hyewon
AU - Kim, Mi Jeong
AU - Lee, Yun Sang
AU - Jeong, Jae Min
AU - Chung, June Key
AU - Kang, Keon Wook
AU - Xie, Lin
AU - Zhang, Ming Rong
AU - Cheon, Gi Jeong
N1 - Funding Information:
This study was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea to Gi Jeong Cheon (grant HI14C1072), by a grant from the National Research Foundation to Hai-Jeon Yoon (2015R1C1A2A01054113) and to Keon Wook Kang (2015M3D6A1065663), and by a grant from the Global Core Research Center (GCRC) (no. 2011-0030001) to June-Key Chung. No other potential conflict of interest relevant to this article was reported.
Publisher Copyright:
COPYRIGHT © 2018 by the Society of Nuclear Medicine and Molecular Imaging.
PY - 2018/5/1
Y1 - 2018/5/1
N2 - Activated macrophages have been known to play pivotal roles in the pathogenesis of rheumatoid arthritis (RA). 18 F-FEDAC (N-benzyl-N-methyl-2-[7,8-dihydro-7-(2- 18 F-fluoroethyl)-8-oxo-2-phenyl-9H-purin-9-yl]acetamide) is a radiolabeled ligand for the 18-kDa translocator protein (TSPO), which is abundant in activated macrophages. We evaluated the feasibility of using 18 F-FEDAC in a murine RA model. Methods: RAW 264.7 mouse macrophages were activated by lipo-polysaccharide. TSPO expression levels in activated and inactivated macrophages were measured by quantitative polymerase chain reaction and Western blotting. The cellular uptake and specific binding of 18 F-FEDAC were measured using a g-counter. For the in vivo study, collagen-induced arthritis (CIA) was developed in DBA/1 mice, and the clinical score for arthritis was measured regularly. 18 F-FEDAC and 18 F-FDG PET images were acquired on days 23 and 37 after the first immunization. Histologic examinations were performed to evaluate macrophages and TSPO expression. Results: We found increased TSPO messenger RNA and protein expression in activated macrophages. Uptake of 18 F-FEDAC in activated macrophages was higher than that in nonactivated cells and was successfully blocked by the competitor, PK11195. In CIA mice, joint swelling was apparent on day 26 after the first immunization, and the condition worsened by day 37. 18 F-FEDAC uptake by arthritic joints increased early on (day 23), whereas 18 F-FDG uptake did not. However, 18 F-FDG uptake by arthritic joints markedly increased at later stages (day 37) to a higher level than 18 F-FEDAC uptake. The 18 F-FEDAC uptake correlated weakly with summed severity score (P = 0.019, r = 0.313), whereas the 18 F-FDG uptake correlated strongly with summed severity score (P, 0.001, r = 0.897). Histologic sections of arthritic joints demonstrated an influx of macrophages compared with that in normal joints. Conclusion: 18 F-FEDAC enabled the visualization of active inflammation sites in arthritic joints in a CIA model by targeting TSPO expression in activated macrophages. The results suggest the potential usefulness of 18 F-FEDAC imaging in the early phase of RA.
AB - Activated macrophages have been known to play pivotal roles in the pathogenesis of rheumatoid arthritis (RA). 18 F-FEDAC (N-benzyl-N-methyl-2-[7,8-dihydro-7-(2- 18 F-fluoroethyl)-8-oxo-2-phenyl-9H-purin-9-yl]acetamide) is a radiolabeled ligand for the 18-kDa translocator protein (TSPO), which is abundant in activated macrophages. We evaluated the feasibility of using 18 F-FEDAC in a murine RA model. Methods: RAW 264.7 mouse macrophages were activated by lipo-polysaccharide. TSPO expression levels in activated and inactivated macrophages were measured by quantitative polymerase chain reaction and Western blotting. The cellular uptake and specific binding of 18 F-FEDAC were measured using a g-counter. For the in vivo study, collagen-induced arthritis (CIA) was developed in DBA/1 mice, and the clinical score for arthritis was measured regularly. 18 F-FEDAC and 18 F-FDG PET images were acquired on days 23 and 37 after the first immunization. Histologic examinations were performed to evaluate macrophages and TSPO expression. Results: We found increased TSPO messenger RNA and protein expression in activated macrophages. Uptake of 18 F-FEDAC in activated macrophages was higher than that in nonactivated cells and was successfully blocked by the competitor, PK11195. In CIA mice, joint swelling was apparent on day 26 after the first immunization, and the condition worsened by day 37. 18 F-FEDAC uptake by arthritic joints increased early on (day 23), whereas 18 F-FDG uptake did not. However, 18 F-FDG uptake by arthritic joints markedly increased at later stages (day 37) to a higher level than 18 F-FEDAC uptake. The 18 F-FEDAC uptake correlated weakly with summed severity score (P = 0.019, r = 0.313), whereas the 18 F-FDG uptake correlated strongly with summed severity score (P, 0.001, r = 0.897). Histologic sections of arthritic joints demonstrated an influx of macrophages compared with that in normal joints. Conclusion: 18 F-FEDAC enabled the visualization of active inflammation sites in arthritic joints in a CIA model by targeting TSPO expression in activated macrophages. The results suggest the potential usefulness of 18 F-FEDAC imaging in the early phase of RA.
UR - http://www.scopus.com/inward/record.url?scp=85046404737&partnerID=8YFLogxK
U2 - 10.2967/jnumed.117.200667
DO - 10.2967/jnumed.117.200667
M3 - Article
C2 - 29326355
AN - SCOPUS:85046404737
SN - 0161-5505
VL - 59
SP - 839
EP - 845
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
IS - 5
ER -